Edit
AveXis, Inc.
https://www.avexis.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 09.01.2025
Active
Discover how Novartis Pharmaceuticals brings innovative medicines to market to enhance health outcomes for patients and offer solutions to healthcare providers.
Location: United States, Illinois, Bannockburn
Employees: 1001-5000
Founded date: 2010
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | PBM Capita... | pbmcap.com |
| - | RA Capital... | racap.com |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 9
| Date | Title | Description |
| 09.01.2025 | Light Horse lassos Novartis partnership worth up to $1B, wrangles $62M series A | Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that could reach up to $1 billion in biobucks. The San Diego-based biotech emerged today with backing from founding inves... |
| 13.04.2021 | AveXis name recognition and Zolgensma legacy hook Lilly in Jaguar's $139M series B | With Eli Lilly on its side and a team of executives with a legacy to build on, Jaguar Gene Therapy has wrapped a $139 million series B funding. Sponsored by Marken Where Discoveries Are Delivered. Move Forward With Marken. If you need to br... |
| 18.09.2019 | Why didn’t nonprofits and the NIH require ‘reasonable’ pricing for Zolgensma? That may happen in France | When a new drug emerges from research largely funded by grants from charities and government agencies, who gets to set the price? In the U.S., that question seems to have been answered — the drug company that makes it. As I’ve learned from ... |
| 01.04.2019 | The top scientist at AveXis told us about this surprising reason that it got bought for $9 billion by Novartis, and it could shape the future of gene therapy | Hollis Johnson/Business Insider Advertisement The biotech AveXis develops cutting-edge "gene therapy" products that could be powerful and long-lasting medical treatments. Swiss drug giant Novartis bought the biotech for $9 billion... |
| 12.10.2018 | Meeting’s nearly fourfold attendance growth highlights cell, gene therapies’ rise | This was a far cry from the first meeting in 2006, when around 350 scientists huddled for warmth against a hostile world. Early gene therapies had ended in disaster, with the deaths of Jesse Gelsinger and others, and federal restrictions we... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 08.09.2015 | AveXis Completes $65M Series D Financing | AveXis, Inc., a Chicago, IL-based gene therapy company developing treatments for rare and life-threatening neurological genetic diseases, completed a $65m Series D financing. The round was led by funds and accounts managed by new investor T... |
| 09.01.2015 | AveXis Raises $10M in Funding | AveXis, a Dallas, Texas-based gene therapy-focused biotech company, raised $10m in funding. The round was led by Deerfield Management and Roche Venture Fund. In conjunction with the funding, Jonathan Leff of Deerfield and Carole Nuechterlei... |
| - | Meeting’s nearly fourfold attendance growth highlights cell, gene therapies’ rise | The Alliance for Regenerative Medicine’s (ARM’s) annual Cell and Gene Meeting needs a bigger boat. Now in its 13th year, the conference attracted more than 1,200 people to Torrey Pines Mesa in San Diego, from October 3 to 5. Last year it dr... |